CSL Behring’s HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Global biotechnology leader CSL announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of HEMGENIX® following a one-time infusion in people living with hemophilia B.